Chronic semaglutide alters ingestive behavior without impairing taste function in mice.
Semaglutide doesn’t mess with taste — at least not in mice. That’s the headline from a new study out of the Monell Chemical Senses Center, where researchers put chronic semaglutide treatment to the test. The focus: does this GLP-1 receptor agonist, famous for its weight loss results, actually blunt taste perception or just change how much animals want to eat?
Mol Metab
by Acosta AA, Ellis H, Hsu FY et al.
“Chronic semaglutide alters ingestive behavior without impairing taste function in mice. Acosta AA(1), Ellis H(1), Hsu FY(1), Yee KK(1), de Lartigue G(2), Alhadeff AL(3). Author information: (1)Monell Chemical Senses Center, Philadelphia PA 19104, USA. (2)Monell Chemical Senses Center, Philadelphia PA 19104, USA; Department of Neuroscience, University of Pennsylvania, Philadelphia PA 19104, USA. (3)Monell Chemical Senses Center, Philadelphia PA 19104, USA; Department of Neuroscience, University of Pennsylvania, Philadelphia PA 19104, USA. Electronic address: aalhadeff@monell.org. Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide are highly effective treatments for obesity, yet the mechanisms by which they reduce food intake remain incompletely understood. Because taste plays a critical role in guiding food intake, several clinical studies have investigated whether GLP-1R agonists alter taste function, but these reports have yielded conflicting results. Here, we systematically tested the effects of chronic semaglutide treatment on taste responsivity in diet-induced obese mice. Mice were evaluated using brief-access gustometer tests to assess responses to sweet, bitter, sour, salty, and fatty tastants. Chronic semaglutide treatment produced robust weight loss but did not alter lick rates for any tastant, indicating intact taste-driven orosensory evaluation across modalities. Psychophysical analysis using a broad range of sucrose concentrations revealed similar concentration-response functions and comparable EC50 values between vehicle- and semaglutide-treated mice, demonstrating unchanged sweet taste sensitivity. However, semaglutide modestly increased total licking and trial initiation for sucrose, suggesting enhanced behavioral engagement rather than altered taste perception. Consistent with the behavioral findings on taste, semaglutide did not affect the abundance of taste receptor cell subtypes in the circumvallate papilla or the expression of genes involved in taste receptor signaling and neurotransmission. Together, these results indicate that chronic semaglutide does not detectably impair peripheral taste function in mice under our experimental conditions. Instead, GLP-1R agonists likely influence ingestive behavior through mechanisms independent of taste signaling, potentially involving alterations in motivational processes. Copyright © 2026 The Author(s). Published by Elsevier GmbH.. All rights reserved.”
The team used diet-induced obese mice and hit them with a battery of taste tests. Sweet, bitter, salty, sour, fatty — every major taste got its own trial. The result? Semaglutide led to clear weight loss but didn’t mess with the animals’ ability to taste. Lick rates and taste-driven behaviors for all flavors stayed steady. Even when they pushed the mice with a wide range of sucrose concentrations, sweet taste sensitivity didn’t budge.
Key takeaway: semaglutide doesn’t impair taste function. Instead, it tweaks ingestive behavior in other ways. Researchers noticed the mice actually initiated more trials and increased total licking for sucrose, hinting at a change in motivation, not basic taste perception.
What about the actual taste buds and the genes behind them? No change. Cell counts in the taste tissue and gene expression markers were rock solid between treated and untreated mice.
For researchers dialing in the mechanisms behind GLP-1 agonists, this matters. The appetite-suppressing action of semaglutide isn’t about dulling taste — it’s about what happens after the first lick. Motivation, not mouthfeel, is likely the main driver.
Anyone sourcing semaglutide for similar work can check the vendor directory for options. Bottom line: in this model, semaglutide changes what mice do, not what they taste.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.